Pregabalin Capsule
Product Images NDC 68788-7524

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 68788-7524). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pregabalin Caps 150mg 30s Count

Pregabalin Capsules 150 mg oral capsules label by Preferred Pharmaceuticals, Inc. The label includes dosage instructions in English and Spanish, indicating to take capsules every certain number of hours. It features storage information, manufacturer details (ScieGen Pharmaceuticals, Inc.), and cautions about federal transfer restrictions.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin at 200 mg three times a day, 100 mg three times a day, 25 mg three times a day, and a placebo group, with distinct lines for each treatment group.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph showing the percent improvement in pain from baseline on the x-axis versus the percent of patients improved on the y-axis. The graph compares outcomes between Pregabalin 100 mg three times a day and placebo, with two lines indicating patient improvement trends for each group.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin at doses of 300 mg, 150 mg, and 75 mg taken two times a day, as well as a placebo, showing the relationship between pain improvement and patient response.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, with the Pregabalin 200 mg group generally showing higher improvement percentages than the other groups.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph depicting percent improvement in pain from baseline plotted against the percent of patients with improvement. The graph compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, showing variations in patient response rates across different levels of pain improvement.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

Bar chart showing responder rates (%) from two studies, Study E1 and Study E3, comparing placebo and various doses of a treatment in mg/day with BID or TID dosing. Study E1 displays response rates from placebo, 50mg/day, 150mg/day, 300mg/day, and 600mg/day doses. Study E3 shows response rates for placebo, 300mg/day BID, and 600mg/day TID doses, indicating statistically significant differences versus placebo for several doses as marked by asterisks.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A dose-response line graph showing seizure reduction (median % change from baseline) on the vertical axis versus dose in mg/day on the horizontal axis, comparing four studies (E1 BID, E2 TID, E3 BID, E3 TID). Significant p-values for seizure reduction at various doses up to 600 mg/day are annotated.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph comparing percent improvement in pain from baseline versus percent of patients improved for Pregabalin at 300 mg, 450 mg, and 800 mg daily doses, and placebo. The horizontal axis shows percent improvement in pain from baseline, and the vertical axis shows the percent of patients improved. Four lines represent each treatment group, with a legend identifying each dose and placebo.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A line graph comparing the estimated percentage of subjects without LTR over time in days for Pregabalin versus Placebo. The y-axis represents the estimated percentage of subjects without LTR from 0% to 100%, while the x-axis shows the duration in days up to 180. Two curves are displayed: a solid line for Pregabalin and a dashed line for Placebo, indicating differences in subject percentages over the study period.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percent of subjects improved versus percent improvement from baseline to Week 12 in a clinical trial. It plots two groups: Pregabalin and Placebo. The Pregabalin group shows a higher percent of subjects improved across the range compared to Placebo, which has a consistently lower improvement percentage.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A Kaplan-Meier curve comparing the percentage of subjects improved over time from baseline to Week 16, showing Pregabalin and placebo groups. The vertical axis represents the percent of subjects improved, and the horizontal axis shows the percentage improved from baseline to Week 16, illustrating a higher improvement trend for Pregabalin compared to placebo.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A formula panel depicting the calculation for creatinine clearance (CLcr) based on age, weight, and serum creatinine, with an adjustment factor for female patients. This is a mathematical expression related to drug dosing or pharmacokinetics rather than product packaging.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of pregabalin, the active ingredient in the product Pregabalin 150 mg capsules by Preferred Pharmaceuticals, Inc. The diagram shows the molecular structure with labeled functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.